University of California, Los Angeles

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, Los Angeles sits in the top decile of US sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count).

897 total trials 158 currently recruiting 622 completed early-phase tilt top decile by trial count

University of California, Los Angeles: 897 sponsored US clinical trials, 158 recruiting.

University of California, Los Angeles sponsors 897 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 622 completed. 98 of these trials are in Phase 3-4 (later-stage) and 194 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 17 trials.

Top-decile sponsor footprint

University of California, Los Angeles ranks in the top decile of sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

622 of 679 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

897 total, page 18 of 18

COMPLETED Phase 2

CBT for Comorbid Anxiety Disorders in Children With Autism, Asperger Syndrome, or PDD-NOS

NCT00280670

COMPLETED NA

Educational Technology to Enhance Diabetes Care - Retention Study

NCT00470860

COMPLETED Phase 3

Transitional Case Management Study

NCT00264329

COMPLETED NA

The Effects of a Dietary Supplement on Exercise Performance in Healthy Older Adults"

NCT01073332

TERMINATED Phase 1

Behavioral Therapy Development for Methamphetamine Abuse

NCT00252434

TERMINATED

Constructing an Insulin-Like Growth Factor-based Prediction Model

NCT00263445

COMPLETED Phase 2

Effects of Protein-Enriched Meal on Liver, Kidney or Bone: a Randomized Controlled Trial

NCT01030354

COMPLETED Phase 2

Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy

NCT00389467

COMPLETED NA

Cognitive-Behavioral Therapy and Tai Chi Chih for Patients With Rheumatoid Arthritis

NCT00072657

COMPLETED NA

Nesiritide - Dilated Cardiomyopathy

NCT00709163

COMPLETED Phase 4

Study of Medication and Placebo Response in Major Depression

NCT00229476

COMPLETED NA

Relationship Training for Children With Autism and Their Peers

NCT00095420

COMPLETED Phase 4

Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome

NCT00241215

COMPLETED Phase 3

Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1

NCT00078117

COMPLETED NA

Clinical Evaluation of Morcher Artificial Iris Diaphragms

NCT00812708

COMPLETED NA

Promoting Adherence to Treatment in Schizophrenia

NCT01125267

COMPLETED Phase 4

Electroencephalography (EEG) Biomarkers of Response in Depression

NCT00759122

COMPLETED Phase 2

Celecoxib in Preventing Lung Cancer in Former Heavy Smokers

NCT00055978

COMPLETED Phase 2

Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?

NCT01210079

COMPLETED Phase 1

Rapamycin vs Methotrexate in Diffuse SSc

NCT00241189

COMPLETED Phase 3

Early Surgical Intervention to Treat Epilepsy

NCT00040326

COMPLETED Phase 1

Testosterone Treatment for Multiple Sclerosis

NCT00405353

COMPLETED Phase 4

Estrogen and Perimenopausal Depression

NCT00229450

COMPLETED

Study of Genetic Differences in People With Depression

NCT00229463

COMPLETED NA

Animal-Assisted Therapy for Hospitalized Heart Failure Patients

NCT00391456

COMPLETED Phase 1

Evaluating the Effectiveness of Family-Focused Psychoeducation in Treating Adolescents With Bipolar Disorder

NCT00571402

COMPLETED Phase 4

Physiologic Monitoring of Antidepressant Treatment Response

NCT00759317

COMPLETED NA

Online Family Support and Education for Schizophrenia

NCT00046085

COMPLETED Phase 3

Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1

NCT00032955

COMPLETED Phase 3

Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1

NCT00032968

COMPLETED NA

Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs

NCT00065169

COMPLETED Phase 3

Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial

NCT00009230

COMPLETED Phase 4

Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

NCT00183625

COMPLETED Phase 2

Effects of Parental Behavior on Child Anxiety Regulation

NCT00593515

COMPLETED Phase 4

Improving Work Outcome in People With Recent-onset Schizophrenia

NCT00203788

COMPLETED

Study of Ischemic Colitis Compared to Other Diagnoses in Patients With Lower Gastrointestinal Bleeding

NCT01078324

COMPLETED NA

Comparison Between Two Endoscopic Treatments of Bleeding Internal Hemorrhoids:Band Ligation and Electrocoagulation Probe

NCT00630669

COMPLETED Phase 2

Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6

NCT00000303

COMPLETED Phase 4

Physiologic Monitoring of Antidepressant Response

NCT00792168

COMPLETED Phase 2

Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse/Dependence - 4

NCT00000301

COMPLETED Phase 4

Feasibility Study of Take-Home LAAM Medication - 3

NCT00000300

COMPLETED

Long-term Observation of Patients With Early Rheumatoid Arthritis

NCT00240136

COMPLETED Phase 3

Multicenter Clinical Trial of Buprenorphine - 3

NCT00000207

COMPLETED Phase 2

Clinical Rescue Protocol - 2

NCT00000206

COMPLETED Phase 3

Buprenorphine Maintenance Protocol - 1

NCT00000205

COMPLETED

Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women

NCT01366742

COMPLETED Phase 1

Mentored Patient-Oriented Research Career Development Award

NCT00203684

← Previous Page 18 of 18

Phase Distribution

PhaseTrial count
Phase 1 112
Phase 2 82
Phase 3 22
Phase 4 76

What is open in the University of California, Los Angeles pipeline

158 recruiting of 897 indexed (18% open); 622 completed (69%).

Phase mix: 98 late (III/IV) vs 194 early (I/II) (early-phase heavy).

Top condition: Depression (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, Los Angeles: open-pipeline peers nationwide

Peers matched on 897 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 5%10%15%20% Total trials Recruiting share University of California, Los AngelesIndiana UniversityHoffmann-La RocheBrigham and Women's HospitalUniversity of Texas Southwestern Medical CenterConvaTecEndologixNational Institute on Deafness and Other Communication Disorders (NIDCD)NICHD Pelvic Floor Disorders Network
University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 897 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this University of California, Los Angeles page

897 registered trials is a research-attention snapshot, not an endorsement of University of California, Los Angeles or any single study.

  • 158 of University of California, Los Angeles's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition University of California, Los Angeles studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Los Angeles pipeline card: 897 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.